Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NewBiotics Inc.

Division of Kiadis Pharma Netherlands BV

Latest From NewBiotics Inc.

Athelas Ltd.

Geneva-based start up Athelas Ltd. aims to develop anti-infective drugs based on new bacterial targets it discovers through its DiVi platform. The company's platform is based on the use of the amoeba as a model organism--by engineering single-gene mutant bacteria and infecting the amoebas with those bacteria, Athelas' scientists aim to identify drug targets that may be important in vivo, but that might not be found via traditional in vitro screening methods.
BioPharmaceutical Europe

Antibiotics: Start-Ups Ply Novel Targets and Technologies

Microbial drug resistance is a real and growing problem, but drugmakers face disincentives: a plethora of products already on the market, the difficulty of differentiating drugs, and the habit of reserving truly new drugs for emergencies. Big Pharmas are backing out, creating opportunities for small companies who feel they can play successfully. But lack of interest from large partners means biotechs can't access the assets those firms hold, so many start-ups are pairing up with peers. Some firms are building businesses around an abundance of targets derived through genomics. But others are deliberately avoiding working with novel genetic code and instead studying whole cells and physiological changes in organisms. Many firms are addressing the lack of chemical diversity against targets. Some of these are pursuing diversity through natural products like marine microbes, insisting they'll fare better than earlier firms did, in part because of technological advances. Others are trying to create diversity synthetically, by taking structural approaches to understanding targets new and old, as well as compounds. Crystallography, in silico libraries, computational models and mass spectroscopy are key tools in iterative development processes that remain unproven in the anti-infectives field. Some firms are seeking to minimize the risks of novelty, by putting their efforts into developing new versions of antibiotics that worked well before resistance grew. No matter what technological approach start-ups take to developing antibiotics, all face similar challenges external to themselves-primarily in regulatory affairs and funding, but also in hunting Big Pharma partnerships.
BioPharmaceutical Strategy

NewBiotics Inc.

NewBiotics Inc. is harnessing the power of the thymidylate synthase (TS) enzyme. TS, which is involved in DNA synthesis, normally is overexpressed in tumor cells, leading to resistance to chemotherapeutic agents. NewBiotics is designing prodrugs that are activated by TS inside the cell, leading to programmed cell death instead of chemoprotection.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Kiadis Pharma Netherlands BV
  • Senior Management
  • Thomas Mizelle, CEO
    Chris Headrick, CFO
    H. Michael Shepard, PhD, President & CSO
    Paul Cossum, PhD, EVP, Drug. Dev.
    Raymond Poon, PhD, EVP, Bus. Dev. & Oper.
  • Contact Info
  • NewBiotics Inc.
    Phone: (858) 259-8600
    11760 Sorrento Valley Rd.
    Ste. E
    San Diego, CA 92121